Taxanes in the treatment of breast cancer: A prodigy comes of age

Kathy D. Miller, George W. Sledge

Research output: Contribution to journalReview article

45 Scopus citations


The taxanes, paclitaxel and docetaxel, are among the most promising new agents in the treatment of breast cancer. Responses are routinely seen in >30% of patients with metastatic disease, including those who have previously received anthracyclines. Combination therapy has increased response rates but as yet has not improved the overall survival of patients with metastatic disease. Improved survival with the addition of paclitaxel to standard adjuvant therapy reported in a recently completed trial suggests the true impact of the taxanes has not yet been realized.

Original languageEnglish (US)
Pages (from-to)121-136
Number of pages16
JournalCancer Investigation
Issue number2
StatePublished - 1999


  • Breast cancer
  • Chemotherapy
  • Docetaxel
  • Paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Taxanes in the treatment of breast cancer: A prodigy comes of age'. Together they form a unique fingerprint.

  • Cite this